Abstract Introduction: The cannabinoid Δ9-tetrahydrocannabinolic acid (Δ9-THCA) has long been suggested in review articles and anecdotal reports to be anticonvulsant;…
Abstract Objective: Cannabigerolic acid (CBGA), a precursor cannabinoid in Cannabis sativa, has recently been found to have anticonvulsant properties in…
Abstract Dravet syndrome (DS) is a channelopathy, neurodevelopmental, epileptic encephalopathy characterized by seizures, developmental delay, and cognitive impairment that includes…
Abstract Background and Purpose: Cannabis has been used to treat epilepsy for millennia, with such use validated by regulatory approval…
Abstract Voltage-gated sodium (Nav) channels initiate action potentials in excitable tissues. Altering these channels’ function can lead to many pathophysiological…
Abstract Background: Purified cannabidiol (CBD) was administered to highly refractory patients with Dravet (DS) or Lennox–Gastaut (LGS) syndromes in an…
Abstract Background and Aim: Data on the clinical pharmacokinetics of cannabidiol (CBD) are scanty. We explored the effect of demographic…
Abstract Dravet syndrome (DS) is an epileptic syndrome caused by mutations in the Scn1a gene encoding the α1 subunit of…
Abstract Dravet Syndrome (DS) is a severe childhood epilepsy caused by heterozygous loss-of-function mutations in the SCN1A gene encoding brain…
Abstract Background: For the first time in Korea, we aimed to study the efficacy and safety of cannabidiol (CBD), which…